Our Mission

Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare neuropsychiatric conditions such as Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q).

In order to achieve this for our patients and stakeholders, we have assembled an experienced and dedicated team at Zynerba; together, we have a proven development and commercialization track record and extensive experience in transdermal delivery, rare diseases and conditions, neurology, and psychiatry.

You are now leaving the Zynerba website

You are being redirected to a third-party website. The terms and conditions of this third-party website may be different from zynerba.com and will govern your use of such website.

Continue (5) Cancel